34 related articles for article (PubMed ID: 28076825)
21. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).
Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM
Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547
[TBL] [Abstract][Full Text] [Related]
23. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
24. Recent
Batista VF; Pinto DCGA; Silva AMS
Expert Opin Drug Discov; 2022 Jun; 17(6):603-618. PubMed ID: 35333138
[TBL] [Abstract][Full Text] [Related]
25. Spirocyclic Motifs in Natural Products.
Chupakhin E; Babich O; Prosekov A; Asyakina L; Krasavin M
Molecules; 2019 Nov; 24(22):. PubMed ID: 31744211
[TBL] [Abstract][Full Text] [Related]
26. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
27. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
28. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
Defossa E; Wagner M
Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
Sharma N; Bhagat S; Chundawat TS
Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
[TBL] [Abstract][Full Text] [Related]
30. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
31. Ligands at Free Fatty Acid Receptor 1 (GPR40).
Hara T
Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
